China-based CanSino Biologics, one of the leads in the COVID-19 vaccine race, inked a deal with Pfizer for one of its products. They executed an agreement with the U.S. global pharmaceutical giant in which Pfizer will promote Menhycia, the Chinese company’s meningitis vaccine candidate in China.
This vaccine purportedly offers protection against severe infectious disease triggered by Neisseria meningitidis bacteria, mostly impacting children between the ages of six months to five years old. The product has yet to be approved by the China National Medical Products Administration.
This is the first time a mainland vaccine development has been endorsed especially after the country was hit by a scandal that triggered a crisis of confidence in the domestic vaccine industry, reported anonymous pharma executives.
CanSino Biologics Co-Founder
Yu Xuefeng, co-founder and chairman of CanSino Biologics, reports, “The agreement paves a way for a deepened tie-up with Pfizer and strengthens our commercial capabilities.” He continued, “It also lays a solid foundation for CanSino to consolidate a foothold in China while going international.”